Literature DB >> 28341329

Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.

Shuo Zhang1, Yilin Li1, Xiaopeng Guo1, Lu Gao1, Wei Lian1, Yong Yao1, Ming Feng1, Xinjie Bao1, Renzhi Wang1, Bing Xing2.   

Abstract

BACKGROUND: Growth hormone (GH)-secreting pituitary adenoma is a chronic disease characterized by excess levels of GH and insulin-like growth factor 1 (IGF-1). Based on our clinical experience and observations, we identified discordant GH and IGF-1 levels after surgery. The risk factors for this phenomenon are unclear, and individualized cure, control criteria, and management after surgery should be considered.
PURPOSE: This study aims to investigate the factors affecting the discordant GH and IGF-1 levels after pituitary surgery in acromegalic patients.
METHODS: We retrospectively analyzed 146 patients diagnosed with acromegaly caused by GH-secreting pituitary adenoma who had undergone trans-sphenoidal adenectomy (TSA) at Peking Union Medical College Hospital in 2013. Medical histories were obtained for all patients. Hormone levels, biochemical measurements of liver and renal function, and tumor size were recorded before and 3 months after surgery.
RESULTS: Among the GH-cured patients who had normal GH levels after TSA, 39.2% (20 of 51) had elevated IGF-1. Acromegalic patients with elevated IGF-1 and normal GH levels after TSA had a significantly higher mean body mass index and percentage of upper limit of normal range IGF-1 than the cured patients (p < 0.05). A body mass index greater than >25.0 kg/m2 and a percentage of upper limit of normal range IGF-1 higher than 141.5 before TSA might predict the occurrence of hormone-level discordance after surgery.
CONCLUSION: Body mass index and percentage of upper limit of normal range IGF-1 before TSA might constitute prognostic risk factors for discordance in IGF-1 and GH levels in acromegaly. Additional attention should be devoted to potential risk factors for this phenomenon, and methods for modifying the cure and control criteria for acromegaly should be developed.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  acromegaly; growth hormone; insulin-like growth factor 1; pituitary tumor; surgery

Mesh:

Substances:

Year:  2017        PMID: 28341329     DOI: 10.1016/j.jfma.2017.02.014

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  5 in total

1.  Predictors of surgical outcome and early criteria of remission in acromegaly-some controversial issues.

Authors:  Zihao Wang; Bing Xing
Journal:  Endocrine       Date:  2018-06-25       Impact factor: 3.633

2.  Predictors of postoperative biochemical remission in lower Knosp grade growth hormone-secreting pituitary adenomas: a large single center study.

Authors:  S Zhang; J Chen; Y Zhu; H Wang; Z Mao; S Yao; F Akter; Z Wang; B Hu; D Zhu; C Duan; W Chen
Journal:  J Endocrinol Invest       Date:  2022-09-20       Impact factor: 5.467

3.  Preoperative Fasting C-Peptide Acts as a Promising Predictor of Improved Glucose Tolerance in Patients With Acromegaly After Transsphenoidal Surgery: A Retrospective Study of 64 Cases From a Large Pituitary Center in China.

Authors:  Zihao Wang; Lu Gao; Xiaopeng Guo; Chenzhe Feng; Kan Deng; Wei Lian; Ming Feng; Xinjie Bao; Bing Xing
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-01       Impact factor: 5.555

4.  The Effect of Aging on Quality of Life in Acromegaly Patients Under Treatment.

Authors:  Naoki Yamamoto; Shin Urai; Hidenori Fukuoka; Masaaki Yamamoto; Kenichi Yoshida; Masaki Suzuki; Hiroki Shichi; Yasunori Fujita; Keitaro Kanie; Genzo Iguchi; Yutaka Takahashi; Wataru Ogawa
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-03       Impact factor: 5.555

5.  Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria.

Authors:  Masanori Yonenaga; Shingo Fujio; Mika Habu; Hiroshi Arimura; Takaaki Hiwatari; Shunichi Tanaka; Yasuyuki Kinoshita; Hiroshi Hosoyama; Hirofumi Hirano; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-02-23       Impact factor: 1.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.